StreetInsider.com News Articles

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Thu, 10 Sep 2026 07:58:00 -0400

INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24^th Annual Global Healthcare Conference on September 15, 2026. Jeff Simmons, president and CEO, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation will participate in a fireside chat on Tuesday, September 15 at 2:35 p.m. ET.

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Thu, 10 Sep 2026 07:58:00 -0400

Form 4 Elanco Animal Health For: Sep 04 Filed by: VanHimbergen Robert M

Wed, 09 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260909/27043415.html

Form 4 Elanco Animal Health For: Sep 04 Filed by: Modi Rajeev A.

Wed, 09 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260909/27043411.html

Form 4 Elanco Animal Health For: Sep 04 Filed by: Simmons Jeffrey N

Wed, 09 Sep 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260909/27043399.html

Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility

Mon, 31 Aug 2026 09:30:00 -0400

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline

INDIANAPOLIS, IN / ACCESS Newswire / August 31, 2026 / Elanco Animal Health Incorporated (NYSE:ELAN) announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.

"When we announced the expansion two years ago, we recognized that executing the most exciting pipeline in Elanco's history required a

Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility

Mon, 31 Aug 2026 09:30:00 -0400

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline

"When we announced the expansion two years ago, we recognized that executing the most exciting pipeline in Elanco's history required a

Elanco completes $120M Kansas facility expansion for mAb production

Wed, 26 Aug 2026 08:31:36 -0400

Elanco Animal Health Incorporated (NYSE: ELAN) announced the completion of a 25,000-square-foot manufacturing expansion at its Elwood, Kansas facility, representing a $120 million investment aimed at increasing monoclonal antibody (mAb) production capacity.

The expansion increases the site's production capacity by more than four times through new upstream and downstream processing equipment. It also includes a new pilot plant for process development and clinical testing materials, a new quality control laboratory, and additional support spaces. Burns & McDonnell, a Kansas City, Mo.-based design-build firm, led the project. An additional $30 million investment is planned through 2028 for warehousing, bringing the total planned

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility